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Abstract
Background: In the present study, we explored the effects of immediate induction therapy with the anti-tumour
necrosis factor (TNF)α antibody infliximab (IFX) plus methotrexate (MTX) compared with MTX alone and with
placebo (PL) in patients with very early inflammatory arthritis.
Methods: In an investigator-initiated, double-blind, randomised, placebo-controlled, multi-centre trial
(ISRCTN21272423, http://www.isrctn.com/ISRCTN21272423), patients with synovitis of 12 weeks duration in at
least two joints underwent 1 year of treatment with IFX in combination with MTX, MTX monotherapy, or PL
randomised in a 2:2:1 ratio. The primary endpoint was clinical remission after 1 year (sustained for at least
two consecutive visits 8 weeks apart) with remission defined as no swollen joints, 0–2 tender joints, and an
acute-phase reactant within the normal range.
Results: Ninety patients participated in the present study. At week 54 (primary endpoint), 32% of the patients
in the IFX + MTX group achieved sustained remission compared with 14% on MTX alone and 0% on PL. This
difference (p < 0.05 over all three groups) was statistically significant for IFX + MTX vs PL (p < 0.05), but not for
IFX + MTX vs MTX (p = 0.10), nor for MTX vs PL (p = 0.31). Remission was maintained during the second year
on no therapy in 75% of the IFX + MTX patients compared with 20% of the MTX-only patients.
Conclusions: These results indicate that patients with early arthritis can benefit from induction therapy with anti-TNF
plus MTX compared with MTX alone, suggesting that intensive treatment can alter the disease evolution.
Trial registration: The trial was registered at http://www.isrctn.com/ISRCTN21272423 on 4 October 2007 (date
applied)/12 December 2007 (date assigned). The first patient was included on 24 October 2007.
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Background
Rheumatoid arthritis (RA) is a severe chronic inflamma-
tory joint disease that can lead to joint damage and func-
tional impairment. Early therapy with disease-modifying
anti-rheumatic drugs (DMARDs) can improve outcomes
and limit joint damage and irreversible loss of physical
function [1–3]. With the advent of newer therapeutic
agents and treatment strategies [4, 5], the goal of remis-
sion is achievable in a proportion of patients [6–8]. Im-
portantly, patients in clinical remission usually do not
accrue additional joint damage [9, 10]. Despite these
benefits of early therapy, drug-free remission is not at-
tainable in the majority of patients [11, 12].
Early in the course of RA, a unique stage called the
“window of opportunity” may exist. During this stage, key
steps in pathogenesis may be reversible, with DMARD
therapy blocking progression to full disease manifestations
and potentially leading to sustained remission [13, 14].
Several findings provide support for the window of oppor-
tunity hypothesis: an increase in the risk of persistent dis-
ease after several months of arthritis symptoms [15, 16];
differences in immunological abnormalities in very early
compared with established disease [17, 18]; and the ability
of early treatment with a tumour necrosis factor (TNF) in-
hibitor plus methotrexate (MTX) to allow some patients
with RA to achieve a drug-free remission [19, 20]. Infor-
mation on the existence of the window of opportunity on
the basis of current data is limited, however, since some
studies did not have a double-blind design, evaluated only
a very small number of patients and/or were performed
only in a single centre. Furthermore, recent data obtained
in patients with early disease suggest that, in those fulfill-
ing the classification criteria of RA, drug-free remission
after such induction therapy may be uncommon [12, 21].
Very little is known about the pathogenic processes
operative in very early inflammatory arthritis, especially
in those subjects who do not meet the classification cri-
teria of RA [17, 18, 22]. Since remission due to MTX
therapy alone is rare [23], we reasoned that MTX mono-
therapy might not be sufficient to induce lasting remis-
sion, even at this early stage of disease. Moreover, even
though the presence of rheumatoid factor (RF) and
anti-citrullinated protein antibodies (ACPA) has been
found to identify subjects at increased risk of progres-
sing to RA [24], we elected not to limit entry to subjects
that had developed these biomarkers, but rather to
examine a broader group of subjects who had developed
unexplained inflammatory arthritis within the past
3 months in order to determine whether the presence of
these antibodies or even the classification of RA altered
the likelihood of progressing to RA despite intense ther-
apy. The goal of this study, therefore, was to determine
whether intense therapy with MTX plus infliximab (IFX)
compared with MTX alone or placebo had the capacity
to induce long-lasting drug-free remission in subjects
with a very short period of inflammatory arthritis symp-
toms who had not received prior DMARD therapy.
Methods
Study design
The Definitive Intervention in New Onset Rheumatoid
Arthritis (DINORA) study was a double-blind, randomised,
placebo-controlled, multi-centre, investigator-initiated trial
of the effects of anti-TNFα chimeric monoclonal antibody
IFX in combination with MTX in patients with very early
inflammatory arthritis and was conducted at 14 rheumatol-
ogy centres across Europe (three in Austria, four in the
Netherlands, four in Germany, and one each in Greece,
Italy, and Spain). The study design is depicted in
Additional file 1: Figure SA. The trial was registered
at http://www.isrctn.com/ISRCTN21272423. Patient
recruitment started in October 2007 and ended in
February 2012. The study was conducted in accord-
ance with the Declaration of Helsinki. Ethical com-
mittees of each institution approved the study and
all patients gave written informed consent.
Patients and randomisation
Patients were eligible for the trial if they had symptom
duration of 2 to 12 weeks and had synovial swelling
present in at least two joints (66 joint count); at least
one joint must have been a metacarpophalangeal, prox-
imal interphalangeal, or metatarsophalangeal (MTP)
joint; MTP joints only were considered insufficient for
inclusion. Baseline visits were scheduled if clinical joint
swelling (arthritis) by history was present for 12 weeks
and confirmed at two pre-treatment visits between week
2 and week 12 (Additional file 1: Figure SA). Patients
with a positive purified protein derivative (PPD) test or
chest radiograph performed at screening suggesting tu-
berculosis, malignancy, chronic infectious disease, ele-
vated liver enzymes, or patients who were pregnant or
planning to become pregnant within 6 months after the
last infusion were excluded. Furthermore, patients with
a distinct diagnosis made after a routine diagnostic
work-up, such as a connective tissue disease, psoriatic
arthritis, gout, pseudogout, reactive arthritis, or parvo-
virus arthritis, were not eligible. Thus, only patients with
undifferentiated arthritis or early RA [25] were enrolled
in the trial.
Procedures of the study
Patients were randomised into three groups in a 2:2:1 ratio
by a computer generated randomisation list to infliximab
plus methotrexate (IFX +MTX), MTX monotherapy
(MTX), or placebo (PL). For randomisation, patients were
stratified for the use of glucocorticoids (users versus
non-users, see below) and the presence of ACPA (> 7
Stamm et al. Arthritis Research & Therapy  (2018) 20:174 Page 2 of 12
units, measured by enzyme-linked immunosorbent assay
(ELISA)) or high titre RF (> 50 IU/ml by nephelometry),
determined in a central laboratory. Local investigators
were blinded to the results of the central RF and ACPA
testing and were also discouraged from having these tests
performed on site. For reasons of blinding, a “double--
dummy-like” administration of study medication was pur-
sued. Every patient was treated with tablets containing
MTX or PL and with infusions containing IFX or PL. The
study medication code was kept blinded in patients who
discontinued prematurely. Patients were followed until
week 106. For rescue therapy for patients who discontin-
ued treatment, the protocol recommended leflunomide
(20 mg daily without a loading dose) or sulfasalazine (up to
3000 mg/day) with or without low-dose glucocorticoids.
Patients received treatment with IFX +MTX, MTX
alone, or PL. In addition, supportive therapy appropriate
at this early stage of arthritis was allowed in all three
treatment groups. This therapy included non-steroidal
anti-inflammatory drugs and, if necessary, glucocorti-
coids at a dose of no more than 10 mg/day prednisone
or equivalent. MTX was dosed orally according to a
rapid dose escalation scheme: treatment was started at
10 mg/week and increased to 25 mg/week in three steps
with 2-week intervals except in cases of intolerance. IFX
was administered by intravenous infusions at a dose of
3 mg/kg at 0, 2, and 6 weeks, and at 5 mg/kg every
8 weeks thereafter (and thus at higher than the minimal
dose approved for maintenance therapy).
All core set variables were assessed at every visit.
These variables included swollen and tender joint counts
(SJC and TJC; using a 66- and 68-joint count, respect-
ively), patient and evaluator global assessments (PGA
and EGA, on a 100-mm visual analogue scale (VAS)),
patient pain assessment (by VAS), erythrocyte sedimen-
tation rate (ESR; mm/h), C-reactive protein (CRP; mg/
dl), American College of Rheumatology (ACR) 20, 50,
and 70% response rates [26], and the Health Assessment
Questionnaire Disability Index (HAQ) [27]. Further-
more, composite measures of disease activity, such as
Clinical and Simplified Disease Activity Index (CDAI
and SDAI) [28] and Disease Activity Score 28 (DAS28)
using 28-joint counts and ESR [29] were calculated.
Radiographs of hands and feet were taken at baseline,
6 months, 1 year, and 2 years and scored independently
using the Sharp-van-der-Heijde (SvdH) method [30] by
two readers who were blinded to patient characteristics
and group allocation but who were aware of the chrono-
logical order of the films. The joint space narrowing
(JSN) and erosion scores as well as their sum, represent-
ing the total score, were evaluated. The average score of
the two readers was used for the analyses. In addition,
random-effects models were fitted with and without im-
putation and by taking into account the scores from
both readers and the interaction between treatment allo-
cation and study visit to assess if the rate of radiological
progression between the three treatment groups was sig-
nificantly different.
Endpoints
Persistent clinical remission at weeks 46 and 54 com-
pared between all three treatment groups was taken as
the primary endpoint. Clinical remission was defined as
follows: at two consecutive visits, no swollen joint
(66-joint count), 0 to at most 2 tender joints (68-joint
count but counting unilateral MTPs as one joint), and a
CRP level within the normal range (< 0.5 mg/dl) or a
normal ESR (< 25 mm/h). At the time of the study de-
sign, the ACR/European League Against Rheumatism
(EULAR) remission criteria [26] had not yet been devel-
oped. The criteria chosen here, however, are consistent
with these criteria; similar to the Boolean or index-based
remission criteria, they do not allow for more than two
affected joints (sum of swollen or tender) and require a
normal CRP [10, 28].
In all patients, the last infusion of IFX was planned at
week 54 (or earlier, as specified below), whereas MTX
was continued at the same dose until week 58 and then
tapered in all patients over 4 weeks (weekly reduction by
5 mg/week, last dose at week 62). IFX +MTX, MTX, or
PL was discontinued earlier if clinical remission was
attained at two consecutive visits after the 14-week visit.
Thus, for patients who reached clinical remission at
two or more consecutive visits before week 54 (sus-
tained remission), IFX (or PL) was stopped and MTX
(or PL) tapered beginning after the second visit in re-
mission (first planned possible IFX withdrawal at
week 30; Additional file 1: Figure SA). Since the pa-
tients would not know on which regimen they had
achieved remission, no blinded infusions were contin-
ued from that time-point onward. However, as men-
tioned above, to qualify for the primary endpoint,
patients had to have sustained remission until week
54 irrespective of early withdrawal. The study was
continued until week 106 without further study medi-
cation to evaluate long-term maintenance of remis-
sion; blinding of initial treatment assignment
remained intact.
Statistical analysis
The sample size calculation is described in Additional file 2:
Supplement S1. Descriptive statistics were used for baseline
characteristics and demographic data. We applied a strategy
of step-wise hierarchical hypothesis testing [31] to control
for type I error of the primary and key secondary (SDAI
and DAS28 scores) endpoints. The primary endpoint was
analysed at the fixed 46- to 54-week time point (because
two visits were needed to define sustained/persistent
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remission) using Fisher’s exact test. Persistent clinical
remission at weeks 46 and 54 was evaluated as a cat-
egorical variable (in remission or not) and Fisher’s
exact test was calculated for differences over all three
treatment groups. For the primary endpoint analysis,
we applied non-responder imputation (NRI) for di-
chotomous variables from those visits onward at
which patients had missing data or for patients who
started rescue DMARD therapy, and the last observa-
tion carried forward (LOCF) method for continuous
variables. In case of a significant result regarding the
overall difference between all three groups, the pri-
mary endpoint was subsequently assessed comparing
each of two groups, respectively: group 1 (IFX +
MTX) versus 3 (PL), 1 (IFX +MTX) versus 2 (MTX),
and 2 (MTX) versus 3 (PL). Longitudinal data analysis
of clinical remission is described in Additional file 2:
Supplement S2. Secondary endpoints were tested at
years 1 and 2 using either Fisher’s exact test for cat-
egorical variables or Kruskal-Wallis test for continu-
ous data.
Results
Demographic data and patient flow
Of the 122 screened patients, 90 were randomised and
dosed at the baseline visit (Fig. 1). Baseline characteristics
and demographic data are described in Table 1. Table 2
depicts the number of patients in clinical remission in the
three treatment groups at 6 months, 1 year, and 2 years.
Early withdrawal within the first 3 months was seen in
three patients in the IFX +MTX group , in two in the
MTX group, and in one patient in the PL group.
Clinical remission at 1 year
At week 54 (primary endpoint), more patients in the
IFX +MTX group (12/38, 32%) achieved sustained clin-
ical remission compared with 5/36 (14%) on MTX alone
and none (0/16, 0%) on PL. The overall difference across
all three treatment groups showed statistical significance
(p < 0.05; Additional file 1: Figure SB). Upon subsequent
pairwise comparisons, differences in rates of sustained
clinical remission were significant between IFX +MTX
and PL (treatment effect: 32%; p < 0.05), but not between
the IFX +MTX and MTX (treatment effect 18%;
p > 0.05), nor between MTX and PL (treatment effect
14%; p > 0.05). Figure 2 shows sustained remission rates
as defined for the primary outcome in a cumulative way
over time for each of the treatment groups. By week 30,
10 patients (26%) treated with IFX +MTX had already
achieved clinical remission at two consecutive visits and
all these patients sustained clinical remission until weeks
46 and 54. It is noteworthy that almost one in three pa-
tients receiving IFX +MTX, but only one in seven in the
MTX group and none on PL had achieved sustained
clinical remission at 1 year. The number needed to treat
(NNT) to achieve one additional sustained remission at
52 weeks with IFX +MTX was 3 compared with pla-
cebo, while the NNT for MTX alone versus placebo was
7; NNT was 6 when comparing IFX +MTX with MTX
Fig. 1 Patient flow chart; the patient flow of the DINORA study. BL baseline, MTX methotrexate, PPD purified protein derivative, SAE serious
adverse event
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alone. The results of the longitudinal data analysis are
described in Additional file 2: Supplement S3.
Clinical remission at the end of year 2
Maintenance of a remission state until the end of
year 2 differed significantly across the three groups
(p = 0.0210); only 20% of patients in remission on
MTX monotherapy at 54 weeks maintained remission,
whereas this was the case in 75% of those attaining
this state on IFX +MTX despite withdrawal of ther-
apy (p = 0.0140 for the comparison between IFX +
MTX and MTX groups; Table 2). The NNT to
achieve sustained remission at 2 years with IFX +
MTX was 2 compared with treatment with MTX
alone, and 2 compared with placebo; the NNT for
MTX alone versus placebo was 5.
Changes in disease activity and core set variables
At week 54, the proportions of patients with DAS28
< 2.6 and ACR20 responses were significantly different
over all three groups (p < 0.01 for DAS28 < 2.6 and
p < 0.05 for ACR20), as well as pain scores measured
on a VAS (p < 0.05). The stratified differences between
treatment groups revealed significance between the
IFX +MTX and MTX groups (p < 0.05 for DAS28 <
2.6), IFX +MTX and PL (p < 0.001 for DAS28 < 2.6;
p < 0.05 for ACR20; p < 0.05 for pain scores), and be-
tween MTX and PL (p < 0.01 for ACR20; p < 0.01 for
pain scores).
Patients classified as RA or non-RA at baseline
In the IFX +MTX group, 8/26 (30.8%) of the patients
classified as RA [25] achieved clinical remission at the
Table 1 Baseline characteristics of the study sample
IFX +MTX MTX PL P value
Number of patients (n) 38 36 16 0.4440
Female 26 (68.4%) 28 (77.8%) 9 (56.3%) 0.2833
Age (years), mean ± SD 52.1 ± 14.1 52.9 ± 14.0 54.4 ± 11.2 0.9170
Symptom duration (weeks)a, mean ± SD 10.3 ± 2.3 9.4 ± 2.3 9.8 ± 1.8 0.0722
Rheumatoid factor positive 13 (34.2%) 13 (36.1%) 7 (43.8%) 0.7988
Patients who used steroids prior to the study 24 (63.2%) 22 (61.1%) 9 (56.3%) 0.8931
Anti-citrullinated protein antibody positive 18 (47.4%) 16 (44.4%) 7 (43.8%) 0.9563
Patients who meet the ACR/EULAR 2010 classification criteria for RA, 2010 [25] 26 (68%) 19 (53%) 12 (75%) 0.2135
Patients who meet the 1987 ARA classification criteria for RA [35] 22 (58%) 19 (53%) 9 (56%) 0.9049
Health Assessment Questionnaire (0–3) 0.9 ± 0.7 0.9 ± 0.6 0.7 ± 0.7 0.2903
Disease Activity Score 28 (DAS28; based on ESR) 5.0 ± 1.4 4.8 ± 1.3 4.7 ± 1.1 0.8464
Simplified Disease Activity Index (SDAI) 34.3 ± 23.8 31.1 ± 14.4 27.5 ± 20.0 0.4771
Clinical Disease Activity Index (CDAI) 25.1 ± 14.7 26.2 ± 13.9 23.5 ± 11.9 0.8951
Swollen joint count (0–28) 7.2 ± 5.7 6.50 ± 5.1 7.4 ± 4.6 0.7048
Tender joint count (0–28) 9.2 ± 7.3 10.3 ± 7.2 7.8 ± 5.6 0.5263
Visual analogue scale pain (mm) 44.0 ± 29.3 44.2 ± 24.3 44.6 ± 22.7 0.9595
Patient global assessment (mm) 48.6 ± 29.0 47.8 ± 24.7 39.6 ± 21.0 0.5274
Evaluator/physician global assessment (mm) 38.6 ± 18.3 46.3 ± 22.3 44.6 ± 20.7 0.3627
C-reactive protein (mg/dl) 1.71 ± 2.40 1.18 ± 1.88 0.98 ± 1.28 0.5567
Erythrocyte sedimentation rate (ESR; mm/h) 23.2 ± 20.3 20.3 ± 21.2 20.4 ± 12.6 0.8129
Total Sharp-van-der-Heide score 2.8 ± 5.4 3 ± 3.8 4.6 ± 8.6 0.4816
Erosion score 1.2 ± 1.8 1.6 ± 2.2 2.2 ± 4.2 0.6019
Joint space narrowing score 1.6 ± 3.8 1.4 ± 2.2 2.4 ± 4.4 0.5658
Data are shown as mean ± standard deviation or n (%) as appropriate
The parameters showed no significant differences between the three groups at baseline
Tables with additional data on baseline characteristics as well as 1-year data for the patients who were in remission at 1 year are provided in Additional file 2
(Tables SC and SD)
ACR American College of Rheumatology, ARA American Rheumatism Association, EULAR European League Against Rheumatism, IFX infliximab, MTX methotrexate,
PL placebo, RA rheumatoid arthritis
aSymptom duration refers to the first visit when the patients presented themselves at the centres. At the baseline visit, symptom duration of all patients was
12 weeks because baseline visits were scheduled at this time to ensure persistent arthritis for 12 weeks. Patients who had no residual arthritis at the baseline visit
were excluded
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Table 2 Clinical characteristics of the study sample at 6 months, 1 year, and 2 years
IFX + MTX
n = 38
MTX
n = 36
PL
n = 16
Clinical remission (primary endpoint), no. of patients in remission (%)
6 months 10 (26%) 6 (17%) 0
1 year 12 (32%) 5 (14%) 0
2 years 9 (24%) 1 (3%) 3 (19%)
Other definitions of remission, no. of patients in remission (%)
Disease Activity Score 28 (DAS28)
6 months 20 (53%) 11 (31%) 1 (6%)
1 year 24 (63%) 13 (36%) 3 (19%)
2 years 23 (61%) 11 (31%) 5 (31%)
Simplified Disease Activity Index (SDAI)
6 months 16 (42%) 9 (25%) 1 (6%)
1 year 18 (47%) 13 (36%) 1 (6%)
2 years 18 (47%) 13 (36%) 4 (25%)
ACR/EULAR Boolean
6 months 15 (40%) 8 (22%) 0
1 year 13 (34%) 9 (25%) 1 (6%)
2 years 13 (34%) 10 (28%) 4 (25%)
ACR improvement, responders
ACR20
6 months 20 (53%) 18 (50%) 4 (25%)
1 year 22 (58%) 22 (61%) 3 (19%)
2 years 19 (50%) 19 (53%) 3 (19%)
ACR50
6 months 16 (42%) 13 (36%) 1 (6%)
1 year 17 (45%) 16 (44%) 3 (19%)
2 years 14 (37%) 15 (42%) 3 (19%)
ACR70
6 months 15 (40%) 6 (17%) 1 (6%)
1 year 14 (37%) 11 (31%) 2 (13%)
2 years 13 (34%) 11 (31%) 3 (19%)
Other secondary outcome parameters (mean ± SD)
Pain
6 months 17.3 ± 20.3 22.5 ± 25.2 42.7 ± 31.0
1 year 20.9 ± 23.8 18.3 ± 25.3 45.7 ± 31.8
2 years 23.0 ± 25.1 23.3 ± 29.8 43.5 ± 32.8
Swollen joints (28 joints)
6 months 2.3 ± 5.2 2.1 ± 4.5 4.9 ± 5.6
1 year 2.3 ± 5.2 2.1 ± 4.3 5.0 ± 5.6
2 years 2.8 ± 5.6 2.4 ± 4.5 5.1 ± 5.6
Tender joints (28 joints)
6 months 2.9 ± 5.9 4.9 ± 6.2 7.0 ± 6.4
1 year 2.5 ± 5.6 4.2 ± 6.0 7.2 ± 6.8
2 years 3.4 ± 6.5 4.0 ± 6.1 7.1 ± 7.0
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primary endpoint (1 year) compared with 4/12 (33.3%)
of the patients who did not fulfil RA classification cri-
teria. In the MTX group, 2/19 (10.5%) of the patients
classified as RA reached the primary endpoint at 1 year
compared with 3/17 (17.6%) of the patients who did not
fulfil RA criteria (data not shown). When looking at the
2-year outcome in the IFX +MTX group, 5/26 (19%) of
the patients classified as RA [25] achieved clinical remis-
sion compared with 4/12 (33.3%) of the patients who did
not fulfil RA classification criteria. In the MTX group, 1/
19 (5%) patient classified as RA reached the remission at
2 years compared with none who did not fulfil RA cri-
teria (data not shown). Two of the three patients who
were in remission after 2 years in the PL group fulfilled
the RA classification criteria at baseline, and all three PL
patients were ACPA and RF negative. Thus, there was
no difference in outcomes whether patients fulfilled the
ACR/EULAR classification criteria [25] or not. The
presence of RF made a significant difference in the
remission frequency at the 2-year time only point
(Chi square test; p = 0.0399); the presence of ACPA
made no significant difference in the frequency of remis-
sion at 6 months, 1 year, or 2 years.
Radiographic changes
Mean change from baseline of the Sharp-van-der-Heide
scores [30] did not reveal any noteworthy differences be-
tween the three treatment groups (Table 2 and Additional
file 2: Figure SC and Table SA).
Adverse events
The occurrences of adverse events (AEs) and serious ad-
verse events (SAEs) are depicted in Table 3. There were
no statistically significant differences in the number of
patients with AEs between the three treatment groups
(Fisher’s exact test; data not shown).
Table 2 Clinical characteristics of the study sample at 6 months, 1 year, and 2 years (Continued)
IFX + MTX
n = 38
MTX
n = 36
PL
n = 16
Patient global visual analogue scale (VAS; mm)
6 months 17.7 ± 6.5 23.1 ± 24.6 35.1 ± 28.2
1 year 21.2 ± 24.0 18.4 ± 24.7 38.0 ± 29.3
2 years 24.3 ± 25.3 24.8 ± 30.0 35.6 ± 29.5
Evaluator global VAS (mm)
6 months 16.1 ± 22.0 17.2 ± 24.1 34.6 ± 28.0
1 year 14.1 ± 20.8 17.7 ± 24.6 39.3 ± 29.8
2 years 16.6 ± 24.1 18.4 ± 24.7 34.5 ± 31.3
C-reactive protein (mg/dl)
6 months 0.5 ± 0.9 0.6 ± 1.0 0.8 ± 0.9
1 year 0.5 ± 0.9 0.5 ± 1.0 0.7 ± 0.8
2 years 0.6 ± 1.1 0.6 ± 1.0 0.5 ± 0.8
Erythrocyte sedimentation rate (mm)
6 months 14.6 ± 12.2 17.8 ± 12.5 14.9 ± 6.9
1 year 14.6 ± 12.3 18.7 ± 13.0 18.3 ± 9.7
2 years 16.5 ± 14.1 17.6 ± 11.2 16.5 ± 10.7
Health Assessment Questionnaire (HAQ)
6 months 0.30 ± 0.45 0.57 ± 0.64 0.54 ± 0.67
1 year 0.33 ± 0.46 0.52 ± 0.62 0.61 ± 0.66
2 years 0.41 ± 0.52 0.58 ± 0.61 0.62 ± 0.65
X-raysa
6 months −0.02 ± 0.88 0.07 ± 0.23 0.41 ± 1.53
1 year 0.18 ± 1.06 0.16 ± 0.44 0.0 ± 0.41
2 years 0.36 ± 0.95 0.28 ± 0.67 0.63 ± 1.31
Missing data for continuous variables were imputed using last observation carried forward (LOCF). LOCF was also applied from the time points onwards when
patients received other DMARDs as rescue therapy. The denominator for the percentages given is the number of patients initially included in each group and
stays consistent for each year
ACR American College of Rheumatology, EULAR European League Against Rheumatism, IFX infliximab, MTX methotrexate, PL placebo
aMean change of scores ± SD from baseline of Sharp-van-der-Heijde (SvdH) for patients with complete follow-up data at each time point
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Discussion
The present trial in patients with very early arthritis
yields several important findings on the effects of treat-
ment of early inflammatory arthritis with DMARD ther-
apy. First, as in the SAVE trial [32], our study indicated
that spontaneous remission (on placebo and supportive
treatment alone) occurred only very rarely in patients
with undifferentiated arthritis or very early RA of
12 weeks duration. Secondly, we observed that therapy
with anti-TNF plus MTX, while significantly different
from PL regarding all outcomes, produced more than
twice as many stringently defined remissions when com-
pared with MTX alone (32% and 14%, respectively);
while the trend was clear, the difference in response
rates did not achieve statistical significance (p = 0.10).
Thirdly, we found that the majority of those patients
who had remission on IFX +MTX therapy maintained
remission even after withdrawal of all therapies (overall
24% still had clinical remission at 2 years); in contrast,
80% of those on MTX alone lost their remission state,
leaving only 3% of MTX-treated patients in remission at
2 years. Fourthly, the vast majority of patients who
achieved sustained drug-free remission had already
attained this state within 30 weeks, indicating that the
necessity for longer treatment durations to achieve re-
mission does not increase drug-free remission rates. To-
gether, these findings suggest that once joint
inflammation is clinically manifest, symptomatic therapy
does not impact on the course of disease, that initiation
of DMARD therapy is warranted to improve outcomes,
and that early intensive treatment with anti-TNF +MTX
leads to drug-free remission in 1 of 4 patients. When we
assessed other remission definitions, such as SDAI or
Boolean remission criteria or DAS28 < 2.6, we saw even
higher remission rates in the IFX +MTX group at 1 year
(34–63%), but this was also the case for the MTX group
and the difference across all three groups was not sig-
nificant, except for DAS28 < 2.6. These findings might
be due to the heterogeneity of the patients in our study;
furthermore, our data suggest that aggressive therapy is
not always necessary in very early inflammatory arthritis
for obtaining sustained drug-free remission, although we
did not find any respective predictive markers (data not
shown).
In addition to delineating the effects of DMARD therapy
on early inflammatory arthritis, this study provides im-
portant new information on the validity of the window of
opportunity hypothesis. This hypothesis proposes that a
short period of intensive therapy early in the disease
course may reverse the disease process and produce
long-term benefits. Indeed, in this study, almost one-third
of the patients receiving IFX +MTX achieved sustained
remission, with 9/12 (75%) of those who attained remis-
sion in the first year maintaining this state 1 year later
without any treatment (or a total of 9/38 (24%) of the ran-
domised patients). This outcome contrasts with that of
patients treated with MTX alone since only 1 in 7
achieved remission in the first year, with the majority sub-
sequently losing this state; as a result, only 3% of patients
treated with MTX alone had a sustained remission at
2 years. Thus, anti-TNF +MTX induction treatment dem-
onstrated a clear advantage compared with supportive
therapy at 1 year and compared with MTX-only therapy
at 2 years; in contrast, induction with MTX alone failed to
show a significantly better response than placebo. Import-
antly, the active therapies, in particular anti-TNF plus
Fig. 2 Proportions of remissions; percentage of patients who achieved remission for each time point across the treatment groups. The denominator
stays constant, meaning for example in the infliximab (IFX) +methotrexate (MTX) group that the proportion of patients in remission is always divided
by 38 (the total number of patients included in this group at baseline). PL placebo
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MTX, did not appear to cause major serious adverse
events in this early arthritis patient population, with the
two observed serious adverse events occurring in patients
on supportive care.
While one-third of patients treated with IFX +MTX
had a favourable outcome, two-thirds of the patients
treated with these agents did not attain remission within
the first year. This result is disappointing and could
argue against the window of opportunity hypothesis. It is
important to note, however, that our results pertain only
to the combination of IFX +MTX. As shown in other
studies, RA patients can differ in their response to bio-
logical agents, perhaps based on their mode of action,
and we do not know which patients will respond best to
a given targeted therapy [33]. On the other hand, the
study outcome is quite promising, since 1 of 4 patients
with early arthritis did reach drug-free remission after a
short course of an induction therapy with these agents.
Importantly, in contrast to other randomised controlled
trials in early, although established, RA, we did not ob-
serve a gradual decline in responders over the second
year [21, 34], suggesting a true abrogation or reversal of
the disease process.
Our study has several limitations. First, the study may
have been underpowered to show a significant difference
between the IFX +MTX and MTX-alone groups. For the
purposes of this study, we estimated placebo and spon-
taneous remission rates on the basis of previous obser-
vational studies, and the lack of precise data on
remission rates from these trials could have led to diffi-
culties in balancing MTX alone and anti-TNF +MTX re-
sponses. Although our results indicate that the majority
of patients failed to achieve sustained remission on
anti-TNF +MTX, the difference between anti-TNF +
Table 3 Patients with adverse events (AEs) and serious adverse events (SAEs)
Total
n = 90
IFX +MTX
n = 38
MTX
n = 36
PL
n = 16
Adverse events, n (%)
Infectious/parasitic disease 31 (35%) 19 (50%) 9 (25%) 3 (19%)
Malignancy 1 (1%) 0 1 (3%) 0
Disease of blood, blood-forming organs, and immune mechanisms (except arthritis) 1 (1%) 1 (3%) 0 0
Endocrine, nutritional, and metabolic diseases 9 (10%) 2 (5%) 5 (14%) 2 (12%)
Disease of the nervous system 17 (19%) 6 (16%) 9 (25%) 2 (13%)
Diseases of the eye 3 (3%) 1 (3%) 2 (6%) 0
Diseases of circulatory system 16 (18%) 6 (16%) 7 (19%) 3 (19%)
Diseases of respiratory system 43 (48%) 23 (61%) 16 (44%) 4 (25%)
Diseases of the digestive system 37 (41%) 15 (39%) 17 (47%) 5 (31%)
Diseases of the skin and subcutaneous tissue 25 (28%) 12 (32%) 8 (22%) 5 (31%)
Diseases of musculoskeletal system and connective tissue 30 (33%) 15 (39%) 9 (25%) 6 (38%)
Diseases of urogenital system (pregnancy, childbirth, and puerperium) 4 (4%) 2 (5%) 2 (6%) 0
Symptoms, signs, and abnormal clinical and laboratory findings not elsewhere classified 27 (30%) 11 (29%) 11 (31%) 5 (31%)
Injury, poisoning and certain other consequences of external causes 9 (10%) 6 (16%) 3 (8%) 0
External causes of morbidity 1 (1%) 1 (3%) 0 0
Total 120 99 35
SAEs (n = 12)
Hospitalisation due to different reasonsa 4 1 3
Fainted during blood collection prior to administration of study drug 1 0 0
Significantly raised transaminase levels 1 0 0
Hematuria, followed by a diagnosis of bladder cancer 0 1 0
Hypertensive episode 1 h after the last infusion with study drug 0 1 0
Only 4 (0.9%) of all reported AEs and no SAEs were considered definitely related to the study drug. 155 AEs (37%) and no SAEs were regarded as possibly/
probably related to one of the study drugs. No participant died during the 2-year study period. Two SAEs were related to infections (1 gastrointestinal, 1
genitourinary); however, in both cases patients were on PL only. One of these SAEs was related to a malignancy (bladder cancer on MTX monotherapy) and none
to tuberculosis
IFX infliximab, MTX methotrexate, PL placebo
aHyperglycemia (PL), diarrhoea (PL), urinary tract infection (IFX + MTX), urinary tract infection with fever (PL), MTX pneumonitis (opportunistic) infection (IFX +
MTX), significant flare of disease activity (IFX + MTX), myocardial infarction more than half a year after last study drug (MTX), and biliary pancreatitis in a time after
the study medication (IFX + MTX)
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MTX and MTX alone in the first year might have
reached statistical significance with a larger sample size.
Of note, in this regard, patients treated with MTX alone
did not maintain remission until the end of year 2 while
IFX +MTX patients did, suggesting relevant differences
in the effects of combination therapy compared with
monotherapy. The results of our study need to be inter-
preted with caution; however, they do suggest that early
intensive treatment may alter the course of inflammatory
arthritis. One notable unexpected finding was the diffi-
culty of recruiting patients into this study which con-
trasted with our experience from a previous study [32].
We attempted to enrol very early arthritis patients who
had to consent to their participation in a long-term
(2 years) study at one of their first visits to the rheumatol-
ogy centre before many of them had the opportunity to
recognise and accept the implications of a diagnosis of in-
flammatory arthritis and possibly RA. Our experiences
may be useful in planning future investigator-driven stud-
ies with larger sample sizes in this very early arthritis
population of patients.
Conclusions
In conclusion, our study provides encouraging evidence
that a short-term induction therapy with a TNF inhibitor
plus MTX can yield long-term benefit in a considerable
proportion of patients with early arthritis, even after ces-
sation of all therapy. In contrast, the data presented indi-
cate that MTX alone will not produce responses that are
maintained over time. Placebo or supportive treatment
alone neither improves nor reverses disease; these find-
ings represent further evidence that spontaneous remis-
sion is rare once the signs and symptoms of RA have
emerged. While the current study involves only TNF as
a target of biological therapy, the data nevertheless
strongly support the possibility that patients with early
inflammatory arthritis may have a window of opportun-
ity in which disease reversal is possible.
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